Because no randomised controlled trials were identified, this evidence summary includes 10 observational studies that assessed the effects of infliximab for treating active, unstable extrapulmonary ...
Sarcoidosis is a systemic disorder of unknown etiology. Although it may be self-limited and mild enough in some patients not to require therapy, many patients will experience severe symptoms owing to ...
HORSHAM, PA and KENILWORTH, NJ, NOVEMBER 6, 2007—Centocor, Inc., Schering-Plough Corporation, and Mitsubishi Tanabe Pharma Corporation announced today that an estimated one million patients have now ...
Remicade (infliximab) is a prescription drug that’s used to manage certain autoimmune conditions in adults and some children. The drug is usually given as an intravenous (IV) infusion every 8 weeks.
Remicade (infliximab) is a prescription drug that’s used to treat certain autoimmune conditions, such as rheumatoid arthritis. Remicade can cause side effects that range from mild to serious. Examples ...
MALVERN, Pa.--(BUSINESS WIRE)--Dec. 20, 2004--Centocor, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved REMICADE(R) (infliximab) for the treatment of ankylosing ...
Study showed 73% of Remicade-treated patients with active disease had a clinical response. Centocor Ortho Biotech reported positive data from a Phase III Remicade (infliximab) trial evaluating the ...
Phase 3 data show treatment with REMICADE® (infliximab) resulted in rapid, significant improvement and long-term response in patients with moderate to severe plaque psoriasis. Findings from the ...
-- Revised Labeling Allows Crohn's Patients to Benefit from REMICADE When They Do Not Respond to a Full and Adequate Course of Therapy with a Corticosteroid and/or an Immunosuppressant Centocor, Inc.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback